This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -3.77% and -54.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
All You Need to Know About Arcturus Therapeutics (ARCT) Rating Upgrade to Buy
by Zacks Equity Research
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Arcturus Therapeutics (ARCT) Stock a Solid Choice Right Now?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -55.10% and -34.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcturus Therapeutics (ARCT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
by Zacks Equity Research
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
by Zacks Equity Research
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
by Zacks Equity Research
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 86.79% and 153.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
5 High-Flying Stocks Set to Beat on Earnings in Q2 Next Week
by Nalak Das
In line with better-than-expected earnings reports, five companies are set to beat earnings estimates next week.
Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
by Zacks Equity Research
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -54.55% and 25.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -47.06% and -33.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?